Imaging of microglial activation in MS using PET: Research use and potential future clinical application

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Multiple Sclerosis

• Publication date

  2017-04-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1177/1352458516674568PMID 27760860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma.

  2016cited by this paper
• Comment on Analyses and Conclusions of "Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study".

  2016cited by this paper
• Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis

  2016cited by this paper
• Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?

  2016cited by this paper
• Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis

  2016cited by this paper
• Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation

  2016cited by this paper
• (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease.

  2016cited by this paper
• Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.

  2015cited by this paper
• 11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas

  2015cited by this paper
• Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke

  2015cited by this paper
• Multiple sclerosis—a quiet revolution

  2015cited by this paper
• Imaging neuroinflammation in multiple sclerosis using TSPO-PET

  2015cited by this paper
• In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis

  2015cited by this paper
• Multiple sclerosis—a quiet revolution

  2015cited by this paper
• Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.

  2015cited by this paper
• Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque

  2015cited by this paper
• Characterization in Humans of 18F-MNI-444, a PET Radiotracer for Brain Adenosine 2A Receptors

  2015cited by this paper
• The methodology of TSPO imaging with positron emission tomography

  2015cited by this paper
• Automated Reference Region Extraction and Population-Based Input Function for Brain [11C]TMSX PET Image Analyses

  2015cited by this paper
• Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.

  2014cited by this paper
• Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [¹¹C]A-740003 as a novel tracer of neuroinflammation.

  2014cited by this paper
• In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with 18F-PBR111 PET

  2014cited by this paper
• Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study.

  2014cited by this paper
• In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195

  2014cited by this paper
• Molecular imaging of microglia/macrophages in the brain

  2013cited by this paper
• Radiotracers for molecular imaging of cyclooxygenase-2 (COX-2) enzyme.

  2013cited by this paper
• (11) C-labeled and (18) F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain.

  2013cited by this paper
• Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model.

  2013cited by this paper
• Adenosine A2A Receptors in Secondary Progressive Multiple Sclerosis: A [11C]TMSX Brain PET Study

  2013cited by this paper
• (18) F-labeled folic acid derivatives for imaging of the folate receptor via positron emission tomography.

  2013cited by this paper
• In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106

  2013cited by this paper
• Decreased microglial activation in MS patients treated with glatiramer acetate

  2012cited by this paper
• Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems

  2012cited by this paper
• Progressive multiple sclerosis: pathology and pathogenesis

  2012cited by this paper
• Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

  2012cited by this paper
• Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis

  2011cited by this paper
• An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28

  2011cited by this paper
• Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases

  2011cited by this paper
• Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands

  2011cited by this paper
• Multiple sclerosis normal‐appearing white matter: Pathology–imaging correlations

  2011cited by this paper
• Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas

  2010cited by this paper
• Molecular Imaging

  2009cited by this paper
• Adenosine A2A receptor mediates microglial process retraction

  2009cited by this paper
• Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain

  2009cited by this paper
• Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients.

  2008cited by this paper
• CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis

  2008cited by this paper
• Reference and target region modeling of [11C]-(R)-PK11195 brain studies.

  2007cited by this paper
• The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.

  2006cited by this paper
• Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function.

  2006cited by this paper
• Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study

  2005cited by this paper
• PET visualization of microglia in multiple sclerosis patients using [11C]PK11195

  2003cited by this paper
• The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

  2000cited by this paper
• PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis

  1997cited by this paper
• Macrophages in the Brain: Friends or Enemies?

  1994cited by this paper

• Neurological impact of HIV/AIDS and substance use alters brain function and structure

  2025cites this paper
• Glial Cytokine and Metabolic Networks in Progressive Multiple Sclerosis: From Pathophysiology to Biomarkers and Therapeutic Strategies

  2025cites this paper
• The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions

  2025cites this paper
• A role for microglia in mediating the microbiota–gut–brain axis

  2025cites this paper
• The Dual Role of Microglia in Multiple Sclerosis and its Implications for Diagnostics and Repair

  2025cites this paper
• Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)

  2024cites this paper
• Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance

  2024cites this paper
• CD22 blockade aggravates EAE and its role in microglia polarization

  2024cites this paper
• Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

  2023cites this paper
• Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

  2023cites this paper
• White Matter Pathology

  2021cites this paper
• assessment of a mouse model of multiple sclerosis assessment of a mouse model of multiple sclerosis

  2021cites this paper
• Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713

  2021cites this paper
• Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.

  2021cites this paper
• Clinical and neuroimaging findings in MOGAD–MRI and OCT

  2021cites this paper
• Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients

  2020cites this paper
• Microglia in Multiple Sclerosis: Friend or Foe?

  2020cites this paper
• [18F]CB251 PET/MR imaging probe targeting translocator protein (TSPO) independent of its Polymorphism in a Neuroinflammation Model

  2020cites this paper
• Feasibility of Population-Based Input Function for Kinetic Modeling of [11C]-DPA-713

  2020cites this paper
• Novel imaging markers for neuroinflammation in multiple sclerosis

  2019cites this paper
• Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation

  2019cites this paper
• In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET

  2018cites this paper
• Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases

  2018cites this paper
• Positron emission tomography imaging in evaluation of MS pathology in vivo

  2018cites this paper
• 18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis

  2018cites this paper
• MRI in multiple sclerosis: what is changing?

  2018cites this paper
• 18F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis

  2018cites this paper
• A new frontier for amyloid PET imaging: multiple sclerosis

  2018cites this paper
• 2-5-2018 ( 18 ) F-VC 701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis

  2018cites this paper
• Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis.

  2017cites this paper
• Molecular Imaging of Neuroinflammation in Neurodegenerative Dementias: The Role of In Vivo PET Imaging

  2017cites this paper
• Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis

  2017cites this paper
• TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis

  2017cites this paper